Population Pharmacokinetic Study and Individual Dose Adjustments of High‐Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma
- 17 December 2018
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 59 (4) , 566-577
Abstract
High‐dose methotrexate (>0.5 g/m2) is among the first‐line chemotherapeutic agents used in treating acute lymphoblastic leukemia (ALL) and osteosarcoma in children. Despite rapid hydration, leucovorin rescue, and routine therapeutic drug monitoring, severe toxicity is not uncommon. This study aimed at developing population pharmacokinetic (popPK) models of high‐dose methotrexate for ALL and osteosarcoma and demonstrating the possibility and convenience of popPK model–based individual dose optimization using R and shiny, which is more accessible, efficient, and clinician‐friendly than NONMEM. The final data set consists of 36 ALL (354 observations) and 16 osteosarcoma (585 observations) patients. Covariate model building and parameter estimations were done using NONMEM and Perl‐speaks‐NONMEM. Diagnostic Plots and bootstrapping validated the models’ performance and stability. The dose optimizer developed based on the validated models can obtain identical individual parameter estimates as NONMEM. Compared to calling a NONMEM execution and reading its output, estimating individual parameters within R reduces the execution time from 8.7‐12.8 seconds to 0.4‐1.0 second. For each subject, the dose optimizer can recommend (1) an individualized optimal dose and (2) an individualized range of doses. For osteosarcoma, recommended optimal doses by the optimizer resemble the final doses at which the subjects were eventually stabilized. The dose optimizers developed demonstrated the potential to inform dose adjustments using a model‐based, convenient, and efficient tool for high‐dose methotrexate. Although the dose optimizer is not meant to replace clinical judgment, it provides the clinician with the individual pharmacokinetics perspective by recommending the (range of) optimal dose.Keywords
Funding Information
- Research Grants Council, University Grants Committee (CUHK 489813)
This publication has 43 references indexed in Scilit:
- A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in OsteosarcomaTherapeutic Drug Monitoring, 2011
- PharmGKB summaryPharmacogenetics and Genomics, 2011
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic LeukaemiaClinical Pharmacokinetics, 2006
- Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised OsteosarcomaClinical Pharmacokinetics, 2002
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- The Pharmacology and Clinical Use of MethotrexateNew England Journal of Medicine, 1983
- Antineoplastic DrugsDrugs, 1978